Speeches by Stafford.

“Do you have a model in your mind of how that service would be designed in terms of the way you operate?”

“You only started this in February, but what is your anticipation of demand? In the short time that you have had, is demand meeting that expectation or is it below or above the expectation you had?”

“Are you able to give me any numbers on that?”

“First, I have a relatively general question. When it comes to your GLP-1 services, what could the NHS learn from your experience?”

“That would be very helpful. This is a final question from me. Again, what we are trying to do is work out what the NHS can learn from all this. From your in-store experience, what do you think the NHS could learn from those pilots? Has there been any input, either from its side or yours, to share that information to im…”

“You would agree with that?”

“Okay, thank you very much. Have you done any modelling to understand how many more NHS patients digital providers could support, or are you suggesting, Dr Seyan, that you have an almost infinite capacity to deal with as many people as possible, given the model you are describing?”

“That is very helpful. Moving on, we have heard in our evidence—indeed, you have re-emphasised it now—about the potential for digital services to improve access to GLP-1s. What are the practical changes that need to come about to unlock that potential?”

“That is really helpful. Ms Nevinson?”

“Just so I am clear, are you suggesting that the first presentation is the community pharmacy and then they are somehow managed through a digital means, or are you talking solely through the community pharmacy?”

“Thank you. You have expressed that you are doing about 80% of the market already, but do you feel you have the capacity to scale up to meet the potential demand if we were to move to the model that you are describing?”

“What I am trying to do is get a practical idea of numbers. Have any of you done any modelling to say, “We could treat X number more patients if we did this,” just so the Committee can get some idea of the numbers we are talking about here?”

“That is very helpful. This is slightly on a tangent, but in your opinion is the Obesity Pathway Innovation Programme ambitious enough to meet the current demand for GLP-1s?”

“If no one else has anything to add to that, I am going to jump a question I had, because you have touched on it, Dr Doyle. In our evidence gathering, we have heard some very strong calls for the weight management services and treatments like GLP-1s to be nationally commissioned. Is that something you support, and what …”

“It is always a pleasure to follow the hon. Member for Alloa and Grangemouth (Brian Leishman); it is like a greatest hits of the 1970s. At a time when the war in Ukraine continues and instability spreads across the middle east, energy is not simply an economic question but a matter of national security. Yet under this L…”

“If I were being generous, I would say merely that the hon. Member has not listened to my speech or read the motion in front of us. I have not mentioned anywhere that we will be cutting back on renewable energy. If Labour’s position is misguided, the Liberal Democrats’ position is outright reckless. They would pile furt…”

“I understand that the figure is £25 billion, which is a significant injection into the Treasury however we look at it. The simple truth is this: if we increase domestic supply, we can ease pressure on prices, reduce reliance on expensive imported LNG and cut costs. That is not ideology—it is basic economics. The idea t…”

“T7. Given the ongoing national security concerns, including the risk of foreign interference in elections, will the Home Secretary set out what her Department is doing to ensure that individuals convicted of terrorism offences are prevented from standing for elected office in the UK?”

“Will the Minister give way?”

“It is a pleasure to serve under your chairmanship, Mr Mundell. My constituents have a clear expectation that we proceed with caution when it comes to children’s healthcare, but there is a fundamental contradiction at the heart of this trial: the Government have already restricted these drugs due to what they described …”